Biotech stock poised to gain big from US bank crisis

Dear Reader,  The United States is facing a critical moment.  Debt ceiling negotiations remain tense, with no resolution in sight.  The Treasury Department has issued warnings that the US could default as early as June 1, highlighting the urgent need for a swift resolution.  Adding to the complexity, the US is also grappling with a banking crisis, delivering a double blow to the nation's economy.  However, amidst this ticking time bomb, an unexpected opportunity arises as the market readjusts itself.  Today, we direct your attention to small-cap biotech stocks.  Right now, Apple boasts a higher market value than the combined worth of the 2,000 small-cap companies in the Russell 2000 index—a staggering $100 billion difference.  Why is this the case?  The answer lies in the recent downfall of numerous regional bank stocks within the Russell 2000 index.  Fortunately, the index is taking steps to recalibrate its holdings, and reputable financial institution Goldman Sachs has set its sights on biotech stocks.  One standout player in this sector is [Mainz Biomed (NASDAQ: MYNZ)](.  Since we began coverage in this company, its stock has consistently maintained a share price right around the $5 mark, and several upcoming catalysts could further tip the scales in its favor.  If you had gotten in on this stock when we first began coverage at $3.99, you’d already be up over 25% in three weeks!  [Mainz Biomed]( has already obtained approval and commenced marketing its primary early cancer detection product in the European Union, making it only a matter of time before the US Food and Drug Administration (FDA) grants its availability in the United States.  It comes as no surprise that prominent analysts from HC Wainwright, JonesTrading, and Cantor Fitzgerald have bestowed buy or overweight ratings upon this company.  The potential for success in Mainz Biomed is palpable.  This is undoubtedly a narrative you cannot afford to overlook.  [Conduct your research and click here to access key information on this undervalued NASDAQ stock.](     Disclaimer: Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities. --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for Mainz Biomed (NASDAQ:MYNZ) from Market Jar Media, Inc. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $3000. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Mainz Biomed (NASDAQ:MYNZ) or Market Jar Media, Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Mainz Biomed (NASDAQ:MYNZ) on StreetSignals website for additional information about the relationship between Market Jar Media, Inc and Mainz Biomed (NASDAQ:MYNZ). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com